Pages that link to "Q50888050"

The following pages link to Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels (Q50888050):

Displaying 27 items.

• Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection (Q33683302) (← links)
• Homocysteine, B vitamins, and coronary artery disease (Q33843655) (← links)
• Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. (Q34007712) (← links)
• Homocysteine and coronary risk (Q34027229) (← links)
• Homocysteine in postmenopausal women and the importance of hormone replacement therapy (Q34395845) (← links)
• How progestins influence the cardiovascular effect of hormone replacement therapy. (Q34847431) (← links)
• Homocysteine, folic acid and B-group vitamins in obstetrics and gynaecology (Q35089478) (← links)
• Estrogens ,homocysteine ,vasodilatation and menopause: basic mechanisms ,interactions and clinical implications (Q35540815) (← links)
• What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women? (Q35583454) (← links)
• Homocysteine, estrogen and cognitive decline. (Q36477867) (← links)
• Effects of dydrogesterone on the vascular system (Q36974408) (← links)
• Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels (Q36974411) (← links)
• The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. (Q40735061) (← links)
• A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine (Q42165328) (← links)
• Effects of tibolone on plasma homocysteine levels in postmenopausal women (Q44077014) (← links)
• Effects of estrogen and psychological stress on plasma homocysteine levels (Q44303594) (← links)
• A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels (Q44303596) (← links)
• Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women (Q44303643) (← links)
• Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals (Q44430829) (← links)
• Effects of low‐dose 17‐β‐estradiol plus norethisterone acetate and tibolone on fasting plasma homocysteine levels in postmenopausal women (Q44654914) (← links)
• Effect of hormone replacement therapy and tibolone on serum total homocysteine levels in postmenopausal women (Q44700907) (← links)
• Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. (Q45933093) (← links)
• Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. (Q45946884) (← links)
• Effects of estrogen and estrogen-progestogen therapy on homocysteine levels and their correlation with carotid vascular resistance (Q46973576) (← links)
• Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels (Q51552127) (← links)
• Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women (Q51566279) (← links)
• Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease (Q77571421) (← links)